Viatris Celebrates As US Court Refuses Tecfidera Review
Originator Biogen Is ‘Disappointed With Decision’ And ‘Evaluating Next Steps’
Executive Summary
Viatris has welcomed a decision by the US Court of Appeals for the Federal Circuit not to rehear litigation with Biogen over Tecfidera, after a split decision by the court last year confirmed a patent invalidity ruling that allowed generics to launch in 2020. Biogen told Generics Bulletin it was disappointed with the decision and is evaluating its next steps.